9-27-17 8:09 AM EDT | Email Article


The closing of the first tranche of the private placement (the "offering") of up to 80,000,000 common share purchase warrants (the "warrants") at a price of $0.10 per warrant for proceeds of up to $8,000,000.00 in total is in process with final paperwork and regulatory filings expected to be complete by the end of September, 2017 and the final tranche is expected to be closed and filed by the end of October 2017. 

The Company has granted the Corporate Accountant 50,000 shares at $1.02 per share for $ 51,000.00 in accounting services. In addition, stock options to purchase up to 350,000 common shares at an exercise price of $1.02 per share have also been granted pursuant to the Company’s stock option plan.



Marapharm is a publicly traded company primarily investing in the medical and recreational cannabis space, with corporate operations based in British Columbia, Canada. Since 2016 they have rapidly expanded their footprint to include production locations in the key North American states of Washington, Nevada, and California.  They actively seek expansion opportunities worldwide. 


www.marapharm.com or Linda Sampson, CEO 778-583-4476 email info@marapharm.com  


Facebook:   facebook.com/marapharm

Twitter:  twitter.com/marapharm  


Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, and in Europe, ticker symbol 2Mo on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.

Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.


Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon .   Specifically, there can be no assurance that Marapharm will be issued a final certificate of occupancy or have a final plan for cultivation approved. Furthermore, there can be no assurance that Marapharm’s announced financing activities will be completed in the time frames set out or at all or that they will raise the amount of funds disclosed.

Copyright (c) 2017 TheNewswire - All rights reserved.

Add a Comment

Try Premium Membership today. Your first 14 days are free of charge. Start my Premium Membership Trial.
Sponsored Links
Buy a Link Now
Sponsor Center
Content Partners